MX2022014968A - D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. - Google Patents
D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso.Info
- Publication number
- MX2022014968A MX2022014968A MX2022014968A MX2022014968A MX2022014968A MX 2022014968 A MX2022014968 A MX 2022014968A MX 2022014968 A MX2022014968 A MX 2022014968A MX 2022014968 A MX2022014968 A MX 2022014968A MX 2022014968 A MX2022014968 A MX 2022014968A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- methadone
- methadol
- acetylmethadol
- beta
- Prior art date
Links
- USSIQXCVUWKGNF-KRWDZBQOSA-N dextromethadone Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-KRWDZBQOSA-N 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 210000000653 nervous system Anatomy 0.000 title 1
- 229950004655 dimepheptanol Drugs 0.000 abstract 5
- 229950005506 acetylmethadol Drugs 0.000 abstract 4
- -1 dinoracetylmethadol Chemical compound 0.000 abstract 2
- KYHAUJGXNUJCTC-LPHOPBHVSA-N (3s,6s)-6-(methylamino)-4,4-diphenylheptan-3-ol Chemical compound C=1C=CC=CC=1C(C[C@H](C)NC)([C@@H](O)CC)C1=CC=CC=C1 KYHAUJGXNUJCTC-LPHOPBHVSA-N 0.000 abstract 1
- UPZKJIHNKKJIKX-UHFFFAOYSA-N 2-Ethyl-5-methyl-3,3-diphenyl-1-pyrroline Chemical compound CCC1=NC(C)CC1(C=1C=CC=CC=1)C1=CC=CC=C1 UPZKJIHNKKJIKX-UHFFFAOYSA-N 0.000 abstract 1
- KYHAUJGXNUJCTC-UHFFFAOYSA-N 6-(methylamino)-4,4-diphenylheptan-3-ol Chemical compound C=1C=CC=CC=1C(CC(C)NC)(C(O)CC)C1=CC=CC=C1 KYHAUJGXNUJCTC-UHFFFAOYSA-N 0.000 abstract 1
- IZZIQFNJHDNHIZ-UHFFFAOYSA-N 6-amino-4,4-diphenylheptan-3-ol Chemical compound OC(C(CC(C)N)(C1=CC=CC=C1)C1=CC=CC=C1)CC IZZIQFNJHDNHIZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000008457 Neurologic Manifestations Diseases 0.000 abstract 1
- 206010060860 Neurological symptom Diseases 0.000 abstract 1
- VWCUGCYZZGRKEE-UHFFFAOYSA-N Noracymethadol Chemical compound C=1C=CC=CC=1C(CC(C)NC)(C(OC(C)=O)CC)C1=CC=CC=C1 VWCUGCYZZGRKEE-UHFFFAOYSA-N 0.000 abstract 1
- XBMIVRRWGCYBTQ-UHFFFAOYSA-N acetylmethadol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 229960003701 dextromoramide Drugs 0.000 abstract 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 abstract 1
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- AWZOLILCOUMRDG-UHFFFAOYSA-N edifenphos Chemical compound C=1C=CC=CC=1SP(=O)(OCC)SC1=CC=CC=C1 AWZOLILCOUMRDG-UHFFFAOYSA-N 0.000 abstract 1
- 229940126366 esmethadone Drugs 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 229950009272 isomethadone Drugs 0.000 abstract 1
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 abstract 1
- 229960003221 levopropoxyphene Drugs 0.000 abstract 1
- 229960001797 methadone Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- WCJFBSYALHQBSK-UHFFFAOYSA-N normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 abstract 1
- 229960004013 normethadone Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
- 150000003649 tritium Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
La presente invención se refiere a un método para tratar o prevenir la disfunción celular y la muerte causada por enfermedades genéticas, degenerativas, tóxicas, traumáticas, isquémicas, infecciosas, neoplásicas e inflamatorias y el envejecimiento, y sus síntomas y manifestaciones neurológicas, que incluyen la administración de d-metadona, beta-d-metadol, alfa-I-metadol, beta-I-metadol, alfa-d-metadol, acetilmetadol, d-alfa-acetilmetadol, l-alfa-acetilmetadol, beta-d-acetilmetadol, beta-I-acetilmetadol, d-alfa-normetadol, I-alfa normetadol, noracetilmetadol, dinoracetilmetadol, metadol, normetadol, dinormetadol, EDDP, EMDP, d-isometadona, normetadona, N-metil-metadona, N-metil-d-metadona, N-metil-I-metadona, I-moramida, levopropoxifeno, sales farmacéuticamente aceptables o mezclas de los mismos, incluidos análogos deuterados y tritio, ya sea aislados de su enantiómero o sintetizados de novo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452453P | 2017-01-31 | 2017-01-31 | |
| US201762551948P | 2017-08-30 | 2017-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014968A true MX2022014968A (es) | 2023-01-11 |
Family
ID=61244695
Family Applications (16)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009038A MX2019009038A (es) | 2017-01-31 | 2018-01-31 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014953A MX2022014953A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014973A MX2022014973A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014957A MX2022014957A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014964A MX2022014964A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014977A MX2022014977A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014951A MX2022014951A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014963A MX2022014963A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014962A MX2022014962A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014968A MX2022014968A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014956A MX2022014956A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014966A MX2022014966A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014960A MX2022014960A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014955A MX2022014955A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014971A MX2022014971A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014967A MX2022014967A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
Family Applications Before (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009038A MX2019009038A (es) | 2017-01-31 | 2018-01-31 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014953A MX2022014953A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014973A MX2022014973A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014957A MX2022014957A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014964A MX2022014964A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014977A MX2022014977A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014951A MX2022014951A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014963A MX2022014963A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014962A MX2022014962A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014956A MX2022014956A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014966A MX2022014966A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014960A MX2022014960A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014955A MX2022014955A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014971A MX2022014971A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| MX2022014967A MX2022014967A (es) | 2017-01-31 | 2019-07-30 | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180214395A1 (es) |
| EP (1) | EP3576739A2 (es) |
| JP (2) | JP2020506231A (es) |
| KR (2) | KR20240036125A (es) |
| CN (1) | CN110573159A (es) |
| AU (2) | AU2018215056A1 (es) |
| BR (1) | BR112019015286A2 (es) |
| CA (1) | CA3052273A1 (es) |
| MX (16) | MX2019009038A (es) |
| WO (1) | WO2018144551A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210315865A1 (en) * | 2018-08-16 | 2021-10-14 | Biohaven Therapeutics Ltd. | Use of riluzole oral disintigrating tablets for treating diseases |
| KR20210126628A (ko) * | 2019-01-30 | 2021-10-20 | 유니버시티 오브 파도바 | 질환 및 병태의 예방 및 치료를 위한 구조적으로 변형된 오피오이드 |
| CN109762784B (zh) * | 2019-03-27 | 2021-05-11 | 广州瑞铂茵健康科技有限公司 | 氯氮平在用于延缓培养的间充质干细胞衰老中的应用 |
| KR20220025810A (ko) * | 2019-06-26 | 2022-03-03 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 스미스-마제니스 증후군을 치료하기 위한 방법 및 조성물 |
| BR112022013160A2 (pt) * | 2020-01-03 | 2022-11-08 | Univ Of Padova | Dextrometadona como tratamento modificador de doença para transtornos e doenças neuropsiquiátricos |
| CN113151174B (zh) * | 2021-03-10 | 2022-11-22 | 张君 | 艾司西酞普兰在促进神经干细胞表达bdnf中的应用 |
| AU2022301990A1 (en) * | 2021-06-30 | 2024-01-18 | Charles E. Inturrisi | Modified release formulations of methadone and its isomers, esmethadone and levomethadone and derivatives |
| WO2023066330A1 (zh) * | 2021-10-22 | 2023-04-27 | 苏州澳宗生物科技有限公司 | 依达拉奉在自闭症谱系障碍治疗中的应用 |
| WO2023137059A1 (en) * | 2022-01-12 | 2023-07-20 | The Penn State Research Foundation | Topical naltrexone as a treatment for dry eye |
| WO2023225630A2 (en) * | 2022-05-19 | 2023-11-23 | Virginia Commonwealth University | FORMULATIONS FOR ADMINISTERING LAAM, norLAAM AND dinorLAAM AND METHODS OF THEIR USE TO TREAT OPIOID USE DISORDER |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189054A (en) * | 1990-11-02 | 1993-02-23 | Merrell Dow Pharmaceuticals Inc. | 3-amidoindolyl derivatives and pharmaceutical compositions thereof |
| DE19642043A1 (de) * | 1995-10-23 | 1997-04-24 | Hexal Ag | Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht |
| US6025369A (en) * | 1996-05-03 | 2000-02-15 | The Board Of Regents Of The University Nebraska | N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis |
| DE69837387T2 (de) | 1997-01-22 | 2007-12-13 | Cornell Research Foundation, Inc. | (d)-METHADON, EIN NICHT-OPIOIDES SCHMERZMITTEL |
| US8722714B2 (en) * | 2008-01-16 | 2014-05-13 | The Honk Kong University of Science and Technology | Oxazolidine derivatives as NMDA antagonists |
| KR101138048B1 (ko) * | 2009-11-06 | 2012-04-23 | 성균관대학교산학협력단 | Ｂｄｎｆ의 발현을 증가시키는 신규 펩타이드 및 이를 포함하는 알츠하이머병 또는 파킨슨병의 예방 및 치료용 약학 조성물 |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| US20120128683A1 (en) * | 2011-11-22 | 2012-05-24 | Shantha Totada R | Autism treatment |
| US9468611B2 (en) * | 2012-09-27 | 2016-10-18 | Relmada Therapeutics, Inc. | d-Methadone for the treatment of psychiatric symptoms |
| BR112017015721A2 (pt) * | 2015-01-22 | 2018-04-10 | Mitochon Pharmaceuticals Inc | expressão induzida de fator neurotrófico derivado do cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas. |
| WO2016191763A2 (en) * | 2015-05-28 | 2016-12-01 | Georgetown University | Use of methadone metabolites for treatment of anxiety and depression |
| CN108137483A (zh) * | 2015-08-24 | 2018-06-08 | 科迪实验室公司 | 盐酸左美沙酮或盐酸右美沙酮的合成及其使用方法 |
-
2018
- 2018-01-31 CA CA3052273A patent/CA3052273A1/en active Pending
- 2018-01-31 JP JP2019562230A patent/JP2020506231A/ja active Pending
- 2018-01-31 US US15/884,915 patent/US20180214395A1/en active Pending
- 2018-01-31 EP EP18706021.5A patent/EP3576739A2/en active Pending
- 2018-01-31 MX MX2019009038A patent/MX2019009038A/es unknown
- 2018-01-31 KR KR1020247007370A patent/KR20240036125A/ko not_active Application Discontinuation
- 2018-01-31 AU AU2018215056A patent/AU2018215056A1/en not_active Abandoned
- 2018-01-31 CN CN201880020508.4A patent/CN110573159A/zh active Pending
- 2018-01-31 WO PCT/US2018/016159 patent/WO2018144551A2/en unknown
- 2018-01-31 BR BR112019015286-5A patent/BR112019015286A2/pt active Search and Examination
- 2018-01-31 KR KR1020197025398A patent/KR20190124722A/ko not_active IP Right Cessation
-
2019
- 2019-07-30 MX MX2022014953A patent/MX2022014953A/es unknown
- 2019-07-30 MX MX2022014973A patent/MX2022014973A/es unknown
- 2019-07-30 MX MX2022014957A patent/MX2022014957A/es unknown
- 2019-07-30 MX MX2022014964A patent/MX2022014964A/es unknown
- 2019-07-30 MX MX2022014977A patent/MX2022014977A/es unknown
- 2019-07-30 MX MX2022014951A patent/MX2022014951A/es unknown
- 2019-07-30 MX MX2022014963A patent/MX2022014963A/es unknown
- 2019-07-30 MX MX2022014962A patent/MX2022014962A/es unknown
- 2019-07-30 MX MX2022014968A patent/MX2022014968A/es unknown
- 2019-07-30 MX MX2022014956A patent/MX2022014956A/es unknown
- 2019-07-30 MX MX2022014966A patent/MX2022014966A/es unknown
- 2019-07-30 MX MX2022014960A patent/MX2022014960A/es unknown
- 2019-07-30 MX MX2022014955A patent/MX2022014955A/es unknown
- 2019-07-30 MX MX2022014971A patent/MX2022014971A/es unknown
- 2019-07-30 MX MX2022014967A patent/MX2022014967A/es unknown
-
2024
- 2024-01-11 JP JP2024002598A patent/JP2024032771A/ja active Pending
- 2024-02-19 AU AU2024201053A patent/AU2024201053A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022014977A (es) | 2023-01-04 |
| JP2024032771A (ja) | 2024-03-12 |
| MX2022014962A (es) | 2023-01-11 |
| KR20190124722A (ko) | 2019-11-05 |
| MX2022014963A (es) | 2023-01-11 |
| MX2022014951A (es) | 2023-01-04 |
| MX2019009038A (es) | 2019-12-09 |
| AU2018215056A1 (en) | 2019-08-08 |
| MX2022014964A (es) | 2023-01-11 |
| MX2022014953A (es) | 2023-01-04 |
| MX2022014955A (es) | 2023-01-04 |
| US20180214395A1 (en) | 2018-08-02 |
| WO2018144551A2 (en) | 2018-08-09 |
| MX2022014971A (es) | 2023-01-11 |
| BR112019015286A2 (pt) | 2020-03-03 |
| MX2022014967A (es) | 2023-01-11 |
| CN110573159A (zh) | 2019-12-13 |
| MX2022014957A (es) | 2023-01-11 |
| CA3052273A1 (en) | 2018-08-09 |
| MX2022014956A (es) | 2023-01-11 |
| MX2022014966A (es) | 2023-01-11 |
| WO2018144551A3 (en) | 2018-09-07 |
| AU2024201053A1 (en) | 2024-03-14 |
| MX2022014960A (es) | 2023-01-11 |
| MX2022014973A (es) | 2023-01-11 |
| JP2020506231A (ja) | 2020-02-27 |
| KR20240036125A (ko) | 2024-03-19 |
| EP3576739A2 (en) | 2019-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014964A (es) | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. | |
| MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| MX2023009611A (es) | Esteroides neuroactivos, y su metodo de uso. | |
| SA518400660B1 (ar) | مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2 | |
| JOP20180009A1 (ar) | مركبات مثبط فيروس hiv | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| CR20200149A (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih | |
| PH12016501735A1 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
| MX2022006807A (es) | Análogos de rapamicina y usos de estos. | |
| BR112017025851A2 (pt) | compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo | |
| MX2022002196A (es) | Composición de liberación retardada de niclosamida y uso antiviral de la misma. | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| MX2022004759A (es) | Métodos y composiciones para tratar enfermedades y trastornos hepáticos. | |
| MX2022006333A (es) | Compuesto triheterociclico como inhibidor de jak y uso del mismo. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX2018011592A (es) | Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo. | |
| MX2022012404A (es) | Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. | |
| MX2022008068A (es) | Compuesto para el tratamiento y prevención de trastornos del sistema nervioso central. | |
| MX2022005912A (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria. | |
| MX2023012457A (es) | Compuestos para su uso en el tratamiento de trastornos hiperproliferativos. | |
| JOP20180057A1 (ar) | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |